The U.S. FDA has granted approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), developed by Eli Lilly and Company.

Approved on November 20, 2020, it offers a vital treatment option for managing these rare genetic conditions.

Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia.

Approved on October 14, 2020, it provides a crucial option for managing and treating Ebola virus disease.

7.1-7.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Approved on September 4, 2020, pralsetinib (Gavreto) represents a significant advancement in targeted cancer therapy.

Avidity Biosciences, a U.S. publicly traded company, announced the latest data from the Phase 1/2 clinical trial FORTITUDE that investigates AOC1020 for treating FSHD.

Approved on September 3, 2020, Detectnet (copper Cu 64 dotatate) provides a critical tool for the diagnosis and management of NETs.

KaliVir Immunotherapeutics Receives FDA Approval for Investigational New Drug VET3-TGI in Solid Tumor Immunotherapy.

Approved on August 28, 2020, somapacitan (Sogroya) offers a convenient once-weekly injection, improving adherence and quality of life for patients.

Jul 5th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Approved on August 26, 2020, clascoterone (Winlevi) offers a novel mechanism of action by inhibiting androgen receptors in the skin, reducing oil production and inflammation associated with acne.